You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCaptopril
Accession NumberDB01197  (APRD00164)
TypeSmall Molecule
GroupsApproved
DescriptionCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Structure
Thumb
Synonyms
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
Acepress
Apopril
Capoten
Captolane
Captoprilum
Captopryl
Captoril
Cesplon
CP
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
Dilabar
Garranil
Hypertil
L-Captopril
Lopirin
Tenosbon
Tensobon
Tensoprel
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bci Captopril TabletsTablet50 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet100 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet12.5 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bci Captopril TabletsTablet25 mgOralBaker Cummins IncNot applicableNot applicableCanada
Capoten Tab 100mgTablet100 mgOralBristol Myers Squibb Canada1981-12-312008-02-05Canada
Capoten Tab 12.5mgTablet12.5 mgOralBristol Myers Squibb Canada1990-12-312009-06-29Canada
Capoten Tab 25mgTablet25 mgOralBristol Myers Squibb Canada1981-12-312011-11-01Canada
Capoten Tab 50mgTablet50 mgOralBristol Myers Squibb Canada1981-12-312010-12-16Canada
CaptoprilTablet100 mgOralPharmel Inc1998-09-03Not applicableCanada
CaptoprilTablet25 mgOralSorres Pharma Inc2000-10-262014-06-20Canada
CaptoprilTablet50 mgOralSorres Pharma Inc2000-10-262014-06-20Canada
CaptoprilTablet12.5 mgOralPharmel Inc1998-09-03Not applicableCanada
CaptoprilTablet100 mgOralSorres Pharma Inc2000-10-262014-06-20Canada
CaptoprilTablet25 mgOralPharmel Inc1998-09-03Not applicableCanada
CaptoprilTablet50 mgOralPharmel Inc1998-09-03Not applicableCanada
CaptoprilTablet12.5 mgOralSorres Pharma Inc2000-10-262014-06-20Canada
Captopril TabletsTablet12.5 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril TabletsTablet25 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril TabletsTablet50 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril TabletsTablet100 mgOralIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Captopril-100 Tab 100mgTablet100 mgOralPro Doc Limitee1991-12-312000-07-31Canada
Captopril-12.5 Tab 12.5mgTablet12.5 mgOralPro Doc Limitee1991-12-312009-07-23Canada
Captopril-25 Tab 25mgTablet25 mgOralPro Doc Limitee1991-12-312012-07-23Canada
Captopril-50 Tab 50mgTablet50 mgOralPro Doc Limitee1991-12-312009-07-23Canada
CaptrilTablet12.5 mgOralTechnilab Pharma Inc.1998-06-302004-08-03Canada
CaptrilTablet25 mgOralTechnilab Pharma Inc.1998-06-302004-08-03Canada
CaptrilTablet50 mgOralTechnilab Pharma Inc.1998-06-302004-08-03Canada
CaptrilTablet100 mgOralTechnilab Pharma Inc.1998-06-302004-08-03Canada
Dom-captoprilTablet25 mgOralDominion Pharmacal1998-09-172016-10-25Canada
Dom-captoprilTablet50 mgOralDominion Pharmacal1998-09-172016-10-25Canada
Dom-captoprilTablet100 mgOralDominion Pharmacal1998-09-172016-10-25Canada
Dom-captoprilTablet12.5 mgOralDominion Pharmacal1998-09-172016-10-25Canada
Ftp-captoprilTablet12.5 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-captoprilTablet25 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Ftp-captoprilTablet50 mgOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Med Captopril - Tab 12.5mgTablet12.5 mgOralMedican Pharma Incorporated1996-07-302011-03-29Canada
Med Captopril - Tab 100mgTablet100 mgOralMedican Pharma Incorporated1996-07-092011-03-29Canada
Med Captopril - Tab 25mgTablet25 mgOralMedican Pharma Incorporated1996-08-222011-03-29Canada
Med Captopril - Tab 50mgTablet50 mgOralMedican Pharma Incorporated1996-07-302011-03-29Canada
Mylan-captoprilTablet12.5 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captoprilTablet50 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captoprilTablet100 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-captoprilTablet25 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Novo-captorilTablet6.25 mgOralNovopharm Limited1998-06-022005-08-10Canada
Nu-capto Tab 100mgTablet100 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 12.5mgTablet12.5 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 25mgTablet25 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Nu-capto Tab 50mgTablet50 mgOralNu Pharm Inc1991-12-312012-09-04Canada
Orb-captoprilTablet25 mgOralOrbus Pharma IncNot applicableNot applicableCanada
Orb-captoprilTablet50 mgOralOrbus Pharma IncNot applicableNot applicableCanada
Penta-captopril TabletsTablet12.5 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril TabletsTablet25 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril TabletsTablet50 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-captopril TabletsTablet100 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-captopril - Tab 12.5mgTablet12.5 mgOralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 25mgTablet25 mgOralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 50mgTablet50 mgOralPharmascience Inc1998-06-17Not applicableCanada
PMS-captopril - Tab 100mgTablet100 mgOralPharmascience Inc1998-06-17Not applicableCanada
Ratio-captopril Tab 100mgTablet100 mgOralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 12.5mgTablet12.5 mgOralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 25mgTablet25 mgOralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Ratio-captopril Tab 50mgTablet50 mgOralRatiopharm Inc Division Of Teva Canada Limited1990-12-312006-08-04Canada
Teva-captoprilTablet12.5 mgOralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captoprilTablet25 mgOralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captoprilTablet50 mgOralTeva Canada Limited1991-12-31Not applicableCanada
Teva-captoprilTablet100 mgOralTeva Canada Limited1991-12-31Not applicableCanada
Tria-captopril 100mg TabletTablet100 mgOralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 12.5mg TabletTablet12.5 mgOralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 25mg TabletTablet25 mgOralLaboratoires Trianon IncNot applicableNot applicableCanada
Tria-captopril 50mg TabletTablet50 mgOralLaboratoires Trianon IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-capto Tab 100mgTablet100 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 12.5mgTablet12.5 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 25mgTablet25 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 50mgTablet50 mgOralApotex Inc1990-12-31Not applicableCanada
Apo-capto Tab 6.25mgTablet6.25 mgOralApotex Inc1992-12-31Not applicableCanada
CaptoprilTablet50 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
CaptoprilTablet50 mg/1OralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralWockhardt Limited1997-03-28Not applicableUs
CaptoprilTablet100 mg/1Oralbryant ranch prepack1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
CaptoprilTablet100 mg/1OralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
CaptoprilTablet25 mg/1OralA S Medication Solutions1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
CaptoprilTablet50 mg/1OralCarilion Materials Management1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralCardinal Health2004-02-16Not applicableUs
CaptoprilTablet50 mg/1OralApotex Corp.2005-12-07Not applicableUs
CaptoprilTablet100 mg/1OralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
CaptoprilTablet12.5 mg/1OralWockhardt USA LLC.1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs
CaptoprilTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CaptoprilTablet50 mg/1OralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralRed Pharm Drug Inc.1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
CaptoprilTablet100 mg/1OralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
CaptoprilTablet12.5 mg/1OralUnit Dose Services1997-03-28Not applicableUs
CaptoprilTablet100 mg/1OralSandoz Inc.2016-07-01Not applicableUs
CaptoprilTablet25 mg/1OralPd Rx Pharmaceuticals, Inc.1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
CaptoprilTablet25 mg/1OralRebel Distributors Corp1996-02-13Not applicableUs
CaptoprilTablet100 mg/1OralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralState of Florida DOH Central Pharmacy2009-07-012016-03-11Us
CaptoprilTablet100 mg/1OralWockhardt Limited1997-03-28Not applicableUs
CaptoprilTablet50 mg/1Oralbryant ranch prepack2009-09-11Not applicableUs
CaptoprilTablet25 mg/1OralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
CaptoprilTablet12.5 mg/1OralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralREMEDYREPACK INC.2011-06-162016-10-20Us
CaptoprilTablet12.5 mg/1OralSandoz Inc.2016-07-01Not applicableUs
CaptoprilTablet25 mg/1OralCardinal Health2004-02-16Not applicableUs
CaptoprilTablet100 mg/1OralApotex Corp.2005-12-07Not applicableUs
CaptoprilTablet12.5 mg/1OralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
CaptoprilTablet25 mg/1OralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralWockhardt USA LLC.1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2012-12-13Not applicableUs
CaptoprilTablet25 mg/1OralPhysicians Total Care, Inc.1996-04-25Not applicableUs
CaptoprilTablet100 mg/1OralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralA S Medication Solutions1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1OralWockhardt Limited1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralREMEDYREPACK INC.2014-09-15Not applicableUs
CaptoprilTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
CaptoprilTablet12.5 mg/1OralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralUnit Dose Services1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralRebel Distributors Corp1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralREMEDYREPACK INC.2016-03-11Not applicableUs
CaptoprilTablet12.5 mg/1OralMylan Institutional Inc.1996-02-14Not applicableUs
CaptoprilTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CaptoprilTablet12.5 mg/1OralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
CaptoprilTablet12.5 mg/1Oralbryant ranch prepack1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
CaptoprilTablet30 mg/1OralREMEDYREPACK INC.2013-02-282016-11-16Us
CaptoprilTablet25 mg/1OralSandoz Inc.2016-07-01Not applicableUs
CaptoprilTablet25 mg/1OralCardinal Health2011-04-29Not applicableUs
CaptoprilTablet12.5 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
CaptoprilTablet50 mg/1OralPreferred Pharmaceuticals, Inc.1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralPhysicians Total Care, Inc.1996-08-05Not applicableUs
CaptoprilTablet12.5 mg/1OralApotex Corp.2005-12-07Not applicableUs
CaptoprilTablet25 mg/1OralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
CaptoprilTablet25 mg/1OralRebel Distributors Corp1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralWockhardt USA LLC.1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralWest Ward Pharmaceuticals Corp1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralREMEDYREPACK INC.2014-01-30Not applicableUs
CaptoprilTablet25 mg/1OralNu Care Pharmaceuticals, Inc.1996-02-13Not applicableUs
CaptoprilTablet25 mg/1OralWockhardt Limited1997-03-28Not applicableUs
CaptoprilTablet25 mg/1Oralbryant ranch prepack1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralAidarex Pharmaceuticals LLC1997-03-28Not applicableUs
CaptoprilTablet100 mg/1OralState of Florida DOH Central Pharmacy2009-07-012016-03-02Us
CaptoprilTablet25 mg/1OralMylan Institutional Inc.1996-02-14Not applicableUs
CaptoprilTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CaptoprilTablet25 mg/1OralGolden State Medical Supply, Inc.1996-02-13Not applicableUs
CaptoprilTablet15 mg/1OralRed Pharm Drug Inc.1996-02-13Not applicableUs
CaptoprilTablet100 mg/1OralMylan Pharmaceuticals Inc.1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralGLENVIEW PHARMA INC.1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralWindlas Healthcare (P) Ltd.1997-03-28Not applicableUs
CaptoprilTablet50 mg/1OralUnit Dose Services1996-02-13Not applicableUs
CaptoprilTablet50 mg/1OralSandoz Inc.2016-07-01Not applicableUs
CaptoprilTablet12.5 mg/1OralCardinal Health2011-04-29Not applicableUs
CaptoprilTablet50 mg/1OralSt Marys Medical Park Pharmacy2014-01-16Not applicableUs
CaptoprilTablet50 mg/1OralRebel Distributors Corp1997-03-28Not applicableUs
CaptoprilTablet100 mg/1OralWockhardt USA LLC.1997-03-28Not applicableUs
CaptoprilTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2012-03-29Not applicableUs
CaptoprilTablet12.5 mg/1OralCardinal Health2004-02-16Not applicableUs
CaptoprilTablet25 mg/1OralApotex Corp.2005-12-07Not applicableUs
CaptoprilTablet50 mg/1OralLegacy Pharmaceutical Packaging2009-09-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcepressBernofarm (Indonesia), BMS (Italy)
AceprilBMS (United Kingdom)
AlopresinNot Available
ApoprilNot Available
CapotenBristol-Myers Squibb, Par
CaptolaneSanofi-Aventis (France)
CaptorilNovopharm (Canada)
CesplonEsteve (Spain)
DilabarQualigen (Spain)
GarranilAristegui (Spain)
HipertilNormal (Portugal)
HypertilNormal (Portugal)
LopirinBMS (Germany,Switzerland)
LoprilOrion (Finland), BMS (France)
TenosbonNot Available
TensoprelRubio (Spain)
Brand mixtures
NameLabellerIngredients
Captopril and HydrochlorothiazideMylan Phamaceuticals Inc.
SaltsNot Available
Categories
UNII9G64RSX1XD
CAS number62571-86-2
WeightAverage: 217.285
Monoisotopic: 217.077264041
Chemical FormulaC9H15NO3S
InChI KeyFAKRSMQSSFJEIM-RQJHMYQMSA-N
InChI
InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1
IUPAC Name
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
SMILES
C[[email protected]](CS)C(=O)N1CCC[[email protected]]1C(O)=O
Pharmacology
IndicationFor the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Structured Indications
PharmacodynamicsCaptopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain its effects by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Captopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Captopril’s affinity for ACE is approximately 30,000 times greater than that of ATI.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
72 kDa type IV collagenaseProteinunknown
inhibitor
HumanP08253 details
Matrix metalloproteinase-9Proteinunknown
inhibitor
HumanP14780 details
Leukotriene A-4 hydrolaseProteinunknownNot AvailableHumanP09960 details
Related Articles
Absorption60-75% in fasting individuals; food decreases absorption by 25-40% (some evidence indicates that this is not clinically significant)
Volume of distributionNot Available
Protein binding25-30% bound to plasma proteins, primarily albumin
Metabolism

Hepatic. Major metabolites are captopril-cysteine disulfide and the disulfide dimer of captopril. Metabolites may undergo reversible interconversion.

SubstrateEnzymesProduct
Captopril
Not Available
captopril-cysteine disulfideDetails
Route of eliminationNot Available
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include emesis and decreased blood pressure. Side effects include dose-dependent rash (usually maculopapular), taste alterations, hypotension, gastric irritation, cough, and angioedema.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Captopril Action PathwayDrug actionSMP00146
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Captopril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Captopril.Approved, Investigational
AbirateroneThe serum concentration of Captopril can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Captopril.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Captopril is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Captopril.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Captopril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Captopril is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Captopril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Captopril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Captopril.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Captopril.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Captopril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Captopril.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Captopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Captopril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Captopril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Captopril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Captopril.Approved, Withdrawn
Aluminum hydroxideThe serum concentration of Captopril can be decreased when it is combined with Aluminum hydroxide.Approved
Aluminum phosphateThe serum concentration of Captopril can be decreased when it is combined with Aluminum phosphate.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Captopril.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Captopril.Experimental
AmifostineCaptopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Captopril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Captopril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Captopril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Captopril.Approved
AmiodaroneThe metabolism of Captopril can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Captopril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Captopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Captopril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Captopril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Captopril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Captopril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Captopril is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Captopril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Captopril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Captopril.Approved
ApremilastThe risk or severity of adverse effects can be increased when Captopril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Captopril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Captopril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Captopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Captopril is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Captopril.Approved, Investigational
ArtemetherThe metabolism of Captopril can be decreased when combined with Artemether.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Captopril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Captopril.Approved
AtomoxetineThe metabolism of Captopril can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Captopril.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Captopril.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.Withdrawn
AzathioprineCaptopril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Captopril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Captopril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Captopril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Captopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Captopril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Captopril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Captopril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Captopril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Captopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Captopril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Benoxaprofen.Withdrawn
BepridilCaptopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Captopril.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Captopril.Approved
BethanidineBethanidine may increase the hypotensive activities of Captopril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Captopril is combined with Betulinic Acid.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Captopril.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Captopril can be decreased when it is combined with Bismuth Subcitrate.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Captopril.Approved
BoceprevirThe serum concentration of Captopril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Captopril is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Captopril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Captopril.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Captopril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Captopril.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Captopril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Captopril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Captopril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Captopril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Captopril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Captopril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Captopril is combined with Bupivacaine.Approved, Investigational
BupranololCaptopril may increase the hypotensive activities of Bupranolol.Approved
BupropionThe metabolism of Captopril can be decreased when combined with Bupropion.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Captopril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Captopril.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Captopril.Approved
Calcium carbonateThe serum concentration of Captopril can be decreased when it is combined with Calcium carbonate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Captopril.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Captopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Captopril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Captopril.Experimental
CarbamazepineThe metabolism of Captopril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Captopril is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Captopril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Captopril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Captopril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Captopril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Captopril is combined with Castanospermine.Experimental
CelecoxibThe metabolism of Captopril can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCaptopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Captopril.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Captopril.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Captopril.Approved
ChloroquineThe metabolism of Captopril can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Captopril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Captopril.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Captopril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Captopril.Approved
CholecalciferolThe metabolism of Captopril can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Captopril is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Captopril.Approved
CinacalcetThe metabolism of Captopril can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Captopril.Approved, Investigational
CiprofloxacinCaptopril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Captopril.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Captopril.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Captopril.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Captopril.Approved
ClemastineThe metabolism of Captopril can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Captopril.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Captopril is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Captopril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Captopril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Captopril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Captopril is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Captopril.Approved, Nutraceutical
ClotrimazoleThe metabolism of Captopril can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Captopril.Approved
CobicistatThe serum concentration of Captopril can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Captopril.Approved
CocaineThe metabolism of Captopril can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Captopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Captopril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Captopril.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Captopril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Captopril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Captopril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Captopril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Captopril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Captopril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Captopril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Captopril.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Captopril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Captopril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Captopril.Investigational
DarifenacinThe metabolism of Captopril can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Captopril can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Captopril.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Captopril.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Captopril.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Captopril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Captopril.Investigational
DeserpidineCaptopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Captopril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Captopril.Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Captopril.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Captopril.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Captopril.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Captopril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Captopril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Captopril.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Captopril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Captopril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Captopril.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Captopril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Captopril.Approved
DihydralazineCaptopril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Captopril.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Captopril.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Captopril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Captopril is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Captopril can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Captopril.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Captopril.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Captopril.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Captopril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Captopril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Captopril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Captopril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Captopril.Approved, Investigational
DronedaroneThe metabolism of Captopril can be decreased when combined with Dronedarone.Approved
DrospirenoneCaptopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Droxicam.Approved
DuloxetineCaptopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Captopril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Captopril.Approved
E6201The risk or severity of adverse effects can be increased when Captopril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Captopril is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Captopril.Approved
EfonidipineCaptopril may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Captopril.Approved, Investigational
EliglustatThe metabolism of Captopril can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Captopril.Approved, Vet Approved
EnalaprilatCaptopril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Captopril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Captopril.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Captopril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Captopril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Captopril.Approved
EpoprostenolCaptopril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Captopril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Captopril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Captopril.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Captopril.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Captopril.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Captopril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Captopril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Captopril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Captopril.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Captopril.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Captopril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Captopril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Captopril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Captopril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Captopril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Captopril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Captopril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Captopril is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Captopril.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Captopril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Captopril is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Captopril.Approved
exisulindThe risk or severity of adverse effects can be increased when Captopril is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Captopril.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Captopril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Captopril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Captopril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Captopril.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Captopril.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Captopril.Approved
FimasartanThe risk or severity of adverse effects can be increased when Captopril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Captopril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Captopril is combined with Flunixin.Vet Approved
FluoxetineThe metabolism of Captopril can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Captopril.Approved
FluvoxamineThe metabolism of Captopril can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Captopril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Captopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Captopril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Captopril.Approved, Vet Approved
GarlicThe serum concentration of Captopril can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Captopril.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Captopril.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Captopril.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Captopril.Withdrawn
GuanabenzGuanabenz may increase the hypotensive activities of Captopril.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Captopril.Approved
GuanethidineGuanethidine may increase the hypotensive activities of Captopril.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Captopril.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Captopril.Approved
HalothaneThe risk or severity of adverse effects can be increased when Captopril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Captopril.Approved, Investigational
HexamethoniumCaptopril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Captopril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Captopril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Captopril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Captopril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Captopril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Captopril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Captopril.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Captopril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Captopril.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Captopril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Captopril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Captopril.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Captopril.Approved
IloprostIloprost may increase the hypotensive activities of Captopril.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Captopril.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Captopril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Captopril.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Captopril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Captopril.Approved
IndenololCaptopril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Captopril.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Captopril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Indoprofen.Withdrawn
IndoraminCaptopril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Captopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Captopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Captopril.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Captopril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Captopril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Captopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Captopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Captopril is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Captopril can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Captopril.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Captopril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Captopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Captopril.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Captopril.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Captopril is combined with Kebuzone.Experimental
KetanserinCaptopril may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Captopril.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Captopril.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Captopril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Captopril.Approved
LacidipineCaptopril may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Captopril.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Captopril.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Captopril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Captopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Captopril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Captopril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Captopril is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Captopril.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Captopril.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Captopril.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Captopril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Captopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Captopril is combined with Levobupivacaine.Approved
LevodopaCaptopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Captopril.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Captopril.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Captopril is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Captopril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Captopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Captopril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Captopril.Approved
LofexidineCaptopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Captopril.Approved
LopinavirThe metabolism of Captopril can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Captopril can be decreased when combined with Lorcaserin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Captopril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Captopril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Loxoprofen.Approved
LumefantrineThe metabolism of Captopril can be decreased when combined with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Lumiracoxib.Approved, Investigational
MacitentanCaptopril may increase the hypotensive activities of Macitentan.Approved
MagaldrateThe serum concentration of Captopril can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Captopril can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium hydroxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Captopril is combined with Magnesium salicylate.Approved
Magnesium TrisilicateThe serum concentration of Captopril can be decreased when it is combined with Magnesium Trisilicate.Approved
ManidipineCaptopril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Captopril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Captopril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Captopril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Captopril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Captopril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Captopril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Captopril is combined with Metamizole.Withdrawn
MethadoneThe metabolism of Captopril can be decreased when combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Captopril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Captopril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Captopril.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Captopril.Approved
MethotrimeprazineThe metabolism of Captopril can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Captopril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Captopril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Captopril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Captopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Captopril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Captopril.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Captopril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Captopril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Captopril.Approved, Investigational
MetyrosineCaptopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCaptopril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Captopril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Captopril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Captopril.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Captopril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Captopril.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Captopril.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Captopril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Captopril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Captopril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Captopril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Captopril.Approved, Investigational
MoxonidineCaptopril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Captopril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Captopril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Captopril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Captopril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Captopril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Captopril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Captopril is combined with Naftifine.Approved
NaftopidilCaptopril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Captopril.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Captopril.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Captopril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Captopril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Captopril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Captopril.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Captopril.Approved
NepafenacThe risk or severity of adverse effects can be increased when Captopril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Captopril is combined with Nesiritide.Approved, Investigational
NevirapineThe metabolism of Captopril can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Captopril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Captopril.Approved
NicorandilNicorandil may increase the hypotensive activities of Captopril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Captopril.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Captopril is combined with Niflumic Acid.Approved
NiguldipineCaptopril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Captopril.Approved, Investigational
NilvadipineCaptopril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Captopril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Captopril.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Captopril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Captopril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Captopril.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Captopril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Captopril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Captopril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Captopril.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Captopril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Captopril.Approved
ObinutuzumabCaptopril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Captopril.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Captopril.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Captopril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Captopril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Captopril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Captopril.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Captopril.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Captopril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Captopril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Captopril.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Captopril is combined with Oxaprozin.Approved
OxprenololCaptopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Captopril.Approved, Vet Approved
PanobinostatThe serum concentration of Captopril can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Captopril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Captopril.Approved
ParoxetineThe metabolism of Captopril can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Captopril.Approved
Peginterferon alfa-2bThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Captopril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Captopril.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Captopril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Captopril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Captopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Captopril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Captopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Captopril.Withdrawn
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Captopril.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Captopril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Captopril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Captopril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Captopril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Captopril.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Captopril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Captopril.Approved
PinacidilCaptopril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Captopril.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Captopril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Captopril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Captopril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Captopril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Captopril.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Captopril.Withdrawn
PolythiazideCaptopril may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Captopril.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Captopril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Captopril is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Captopril.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Captopril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Captopril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Captopril.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Captopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Captopril.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Captopril.Approved, Vet Approved
PromazineThe metabolism of Captopril can be decreased when combined with Promazine.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Captopril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Captopril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Captopril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Captopril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Captopril.Approved
PTC299The risk or severity of adverse effects can be increased when Captopril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Captopril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Captopril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Captopril.Approved
QuinidineThe metabolism of Captopril can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Captopril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Captopril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Captopril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Captopril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Captopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Captopril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Captopril.Approved
RescinnamineCaptopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Captopril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Captopril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Captopril.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Captopril.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Captopril.Approved, Investigational
RilmenidineCaptopril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Captopril.Approved
RisperidoneCaptopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Captopril can be decreased when combined with Ritonavir.Approved, Investigational
RituximabCaptopril may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Captopril.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Captopril can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Captopril.Approved, Investigational
RopiniroleThe metabolism of Captopril can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Captopril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Captopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Captopril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Captopril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Captopril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Captopril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Captopril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Captopril.Experimental
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Captopril.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Captopril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Captopril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Captopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Captopril.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Captopril.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Captopril is combined with Seratrodast.Approved, Investigational
SertralineThe metabolism of Captopril can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Captopril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Captopril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Captopril.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Captopril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Captopril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Captopril.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Captopril.Approved, Investigational
SitaxentanCaptopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Captopril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Captopril is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Captopril.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Captopril.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Captopril.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Captopril.Experimental
SpiraprilCaptopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Captopril.Approved
SRT501The risk or severity of adverse effects can be increased when Captopril is combined with SRT501.Investigational
St. John's WortThe metabolism of Captopril can be increased when combined with St. John's Wort.Nutraceutical
StiripentolThe metabolism of Captopril can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Captopril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Captopril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Captopril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Captopril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Captopril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Captopril.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Captopril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Captopril.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Captopril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Captopril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Captopril.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Captopril.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Captopril.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Captopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Captopril.Approved, Investigational
TemocaprilCaptopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Captopril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Captopril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Captopril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.Approved
TerbinafineThe metabolism of Captopril can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Captopril is combined with Teriflunomide.Approved
TerlipressinCaptopril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Captopril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Captopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Captopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Captopril.Approved, Vet Approved
ThioridazineThe metabolism of Captopril can be decreased when combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Captopril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Captopril is combined with Tiaprofenic acid.Approved
TiboloneCaptopril may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Captopril.Approved
TiclopidineThe metabolism of Captopril can be decreased when combined with Ticlopidine.Approved
TicrynafenCaptopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Captopril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Captopril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Captopril.Approved
TipranavirThe serum concentration of Captopril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Captopril.Approved
TolazolineTolazoline may increase the hypotensive activities of Captopril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Captopril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Captopril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Captopril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Captopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Captopril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Captopril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Captopril.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Captopril.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Captopril.Approved
TranilastThe risk or severity of adverse effects can be increased when Captopril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Captopril.Experimental
TranylcypromineThe metabolism of Captopril can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Captopril.Approved
TravoprostTravoprost may increase the hypotensive activities of Captopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Captopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Captopril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Captopril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Captopril.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Captopril.Approved, Vet Approved
TrimazosinCaptopril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Captopril.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Captopril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Captopril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Captopril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Captopril.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Captopril.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Captopril.Approved
UnoprostoneCaptopril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Captopril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Captopril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Captopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Captopril.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Captopril.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Captopril.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Captopril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Captopril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Captopril.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Captopril.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Captopril.Approved, Investigational
VinpocetineCaptopril may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Captopril.Approved
XylometazolineCaptopril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Captopril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Captopril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Captopril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Captopril is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Captopril can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Captopril is combined with Zomepirac.Withdrawn
Food Interactions
  • Captopril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Food decreases absorption by 25 - 40%. Clinical significance is debatable.
  • Herbs that may attenuate the antihypertensive effect of captopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of captopril.
References
Synthesis Reference

Charles M. Zepp, “Methods for preparing captopril and its analogues.” U.S. Patent US5166361, issued July, 1981.

US5166361
General References
  1. Atkinson AB, Robertson JI: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet. 1979 Oct 20;2(8147):836-9. [PubMed:90928 ]
  2. Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA: A new class of angiotensin-converting enzyme inhibitors. Nature. 1980 Nov 20;288(5788):280-3. [PubMed:6253826 ]
  3. Smith CG, Vane JR: The discovery of captopril. FASEB J. 2003 May;17(8):788-9. [PubMed:12724335 ]
External Links
ATC CodesC09AA01C09BA01
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelNot Available
MSDSDownload (37.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.97
Blood Brain Barrier+0.6467
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.6276
P-glycoprotein inhibitor INon-inhibitor0.8448
P-glycoprotein inhibitor IINon-inhibitor0.7415
Renal organic cation transporterNon-inhibitor0.8073
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6293
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9102
CYP450 2D6 inhibitorNon-inhibitor0.9537
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9049
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8975
Ames testNon AMES toxic0.8164
CarcinogenicityNon-carcinogens0.9434
BiodegradationNot ready biodegradable0.6577
Rat acute toxicity1.7403 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9604
hERG inhibition (predictor II)Non-inhibitor0.9118
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
TabletOral12.5 mg
TabletOral25 mg
TabletOral50 mg
TabletOral6.25 mg
TabletOral100 mg/1
TabletOral12.5 mg/1
TabletOral15 mg/1
TabletOral25 mg/1
TabletOral30 mg/1
TabletOral50 mg/1
TabletOral
Prices
Unit descriptionCostUnit
Captopril powder22.03USD g
Capoten 100 mg tablet4.53USD tablet
Capoten 12.5 mg tablet1.8USD tablet
Captopril 100 mg tablet1.53USD tablet
Captopril 50 mg tablet1.14USD tablet
Capoten 25 mg tablet1.13USD tablet
Capoten 50 mg tablet1.13USD tablet
Apo-Capto 100 mg Tablet1.09USD tablet
Mylan-Captopril 100 mg Tablet1.09USD tablet
Novo-Captoril 100 mg Tablet1.09USD tablet
Nu-Capto 100 mg Tablet1.09USD tablet
Captopril 25 mg tablet0.67USD tablet
Captopril 12.5 mg tablet0.62USD tablet
Apo-Capto 50 mg Tablet0.59USD tablet
Mylan-Captopril 50 mg Tablet0.59USD tablet
Novo-Captoril 50 mg Tablet0.59USD tablet
Nu-Capto 50 mg Tablet0.59USD tablet
Apo-Capto 25 mg Tablet0.31USD tablet
Mylan-Captopril 25 mg Tablet0.31USD tablet
Novo-Captoril 25 mg Tablet0.31USD tablet
Nu-Capto 25 mg Tablet0.31USD tablet
Apo-Capto 12.5 mg Tablet0.22USD tablet
Mylan-Captopril 12.5 mg Tablet0.22USD tablet
Novo-Captoril 12.5 mg Tablet0.22USD tablet
Nu-Capto 12.5 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5238924 No1993-08-242010-08-24Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point103-104Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,046,889; September 6, 1977; assigned t o E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,105,776; August 8,1978; assigned to E.R. Squibb & Sons, Inc. Ondetti, M.A. and Cushman, D.W.; U.S. Patent 4,154,840; May 15,1979; assigned to E.R. Squibb & Sons, Inc.
water solubilityFreely solubleNot Available
logP0.34RANADIVE,SA ET AL. (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.52 mg/mLALOGPS
logP1.02ALOGPS
logP0.73ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)4.02ChemAxon
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.61 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.63 m3·mol-1ChemAxon
Polarizability21.72 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentN-acyl-alpha amino acids
Alternative Parents
Substituents
  • N-acyl-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Alkylthiol
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628 ]
  2. Dalkas GA, Marchand D, Galleyrand JC, Martinez J, Spyroulias GA, Cordopatis P, Cavelier F: Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci. 2010 Feb;16(2):91-7. doi: 10.1002/psc.1201. [PubMed:20014331 ]
  3. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. [PubMed:15236580 ]
  4. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016 ]
  5. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]
  6. Tzakos AG, Naqvi N, Comporozos K, Pierattelli R, Theodorou V, Husain A, Gerothanassis IP: The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5084-7. Epub 2006 Aug 2. [PubMed:16889963 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly...
Gene Name:
MMP2
Uniprot ID:
P08253
Molecular Weight:
73881.695 Da
References
  1. Brower GL, Levick SP, Janicki JS: Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3057-64. Epub 2007 Feb 16. [PubMed:17308006 ]
  2. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128 ]
  3. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D: Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer. 1999 May 31;81(5):761-6. [PubMed:10328230 ]
  4. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651 ]
  5. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560 ]
  6. Yamamoto D, Takai S, Hirahara I, Kusano E: Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy. Clin Chim Acta. 2010 May 2;411(9-10):762-4. doi: 10.1016/j.cca.2010.02.059. Epub 2010 Feb 22. [PubMed:20184869 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Gene Name:
MMP9
Uniprot ID:
P14780
Molecular Weight:
78457.51 Da
References
  1. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci. 2008 Dec;108(4):487-94. Epub 2008 Dec 5. [PubMed:19057128 ]
  2. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Korfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart. 2002 Nov;88(5):525-30. [PubMed:12381651 ]
  3. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA: Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005 Nov;31(9):1042-50. Epub 2005 Jul 1. [PubMed:15993560 ]
  4. Yamamoto D, Takai S, Miyazaki M: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol. 2008 Jul 7;588(2-3):277-9. doi: 10.1016/j.ejphar.2008.04.031. Epub 2008 May 22. [PubMed:18501888 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Zinc ion binding
Specific Function:
Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity.
Gene Name:
LTA4H
Uniprot ID:
P09960
Molecular Weight:
69284.64 Da
References
  1. Thunnissen MM, Andersson B, Samuelsson B, Wong CH, Haeggstrom J: Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002 Oct;16(12):1648-50. Epub 2002 Aug 7. [PubMed:12207002 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
other/unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Keire DA, Mariappan SV, Peng J, Rabenstein DL: Nuclear magnetic resonance studies of the binding of captopril and penicillamine by serum albumin. Biochem Pharmacol. 1993 Sep 14;46(6):1059-69. [PubMed:8216349 ]
  2. Lin SY, Wei YS, Li MJ, Wang SL: Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding. Eur J Pharm Biopharm. 2004 May;57(3):457-64. [PubMed:15093593 ]
  3. Mariee AD, Al-Shabanah O: Protective ability and binding affinity of captopril towards serum albumin in an in vitro glycation model of diabetes mellitus. J Pharm Biomed Anal. 2006 May 3;41(2):571-5. Epub 2006 Feb 15. [PubMed:16469467 ]
  4. Narazaki R, Harada K, Sugii A, Otagiri M: Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci. 1997 Feb;86(2):215-9. [PubMed:9040098 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Watanabe K, Sawano T, Terada K, Endo T, Sakata M, Sato J: Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol Pharm Bull. 2002 Jul;25(7):885-90. [PubMed:12132663 ]
  2. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. [PubMed:9733984 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23